Trial · NCT07906314
Post-Market Registry Study for Vibrant Hearing Solutions
NCT07906314, Enrolling by invitation, MED-EL Elektromedizinische Geräte GmbH
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Post-Market Registry Study for Vibrant Hearing Solutions. Trials, record NCT07906314. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07906314
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Post-Market Registry Study for Vibrant Hearing Solutions
- NCT number
- NCT07906314
- Status
- Enrolling by invitation
- Enrollment
- 50 participants, estimated
- Lead sponsor
- MED-EL Elektromedizinische Geräte GmbH
- Conditions
- Conductive Hearing Loss, Mixed Hearing Loss, Sensorineural Hearing Loss, Single Sided Deafness
- First posted
- 2026-10-30
- Last updated
- 2026-11-04
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Patient reported hearing benefit | Data may be analysed at predefined follow-up intervals corresponding to the following time periods after treatment: 0 to 3 months, >3 to 12 months, >12 to 24 months, >24 to 60 months, and beyond 60 months. | Patient reported speech, spatial and qualities of hearing and auditory performance will be assessed by the Speech, Spatial, and Qualities of Hearing questionnaire (SSQ-12 or SSQ P). |
| Secondary | Patient reported health status | Data may be analysed at predefined follow-up intervals corresponding to the following time periods after treatment: 0 to 3 months, >3 to 12 months, >12 to 24 months, >24 to 60 months, and beyond 60 months. | Patient reported health status will be assessed by the Glasgow Benefit Inventory (GBI or GCBI). |
| Secondary | Hearing improvement | Data may be analysed at predefined follow-up intervals corresponding to the following time periods after treatment: 0 to 3 months, >3 to 12 months, >12 to 24 months, >24 to 60 months, and beyond 60 months. | Hearing improvement will be assessed by sound field thresholds (SF). |
| Secondary | Speech intelligibility | Data may be analysed at predefined follow-up intervals corresponding to the following time periods after treatment: 0 to 3 months, >3 to 12 months, >12 to 24 months, >24 to 60 months, and beyond 60 months. | Speech intelligibility will be assessed by the word recognition score (WRS). The Word Recognition Score percentage scale ranges from a minimum value of 0%, which means no words were understood, to a maximum value of 100%, which means all words were understood. |
| Secondary | Speech intelligibility | Data may be analysed at predefined follow-up intervals corresponding to the following time periods after treatment: 0 to 3 months, >3 to 12 months, >12 to 24 months, >24 to 60 months, and beyond 60 months. | Speech intelligibility will be assessed by the speech reception threshold in quiet (SRT) and in noise (SNR) |
| Secondary | Preservation of hearing thresholds | Data may be analysed at predefined follow-up intervals corresponding to the following time periods after treatment: 0 to 3 months, >3 to 12 months, >12 to 24 months, >24 to 60 months, and beyond 60 months. | Preservation of hearing thresholds will be assessed by air conduction thresholds (AC) and /or bone conduction (BC) thresholds. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07906314
GET https://conductscience.org/api/trials/v1/NCT07906314/registered